Skip to main content

US ClosedU.S. Closed

LIMN: Liminatus Pharma, Inc. Class A Common Stock Stock Analysis | finqOS

Healthcare · Biotechnology

Liminatus Pharma, Inc. is an immuno-oncology firm, currently in its clinical development phase, dedicated to pioneering new treatments for cancer.

52W Range

0thpctl

Volume

0.07×avg

Market Cap

5.68MUSD

P/E Ratio

-0.2TTM

Div Yield

-ann

Loading chart data...

Current StateState loading

Liminatus Pharma, Inc. Class A Common Stock

LIMNNASDAQ Global Select·USD·Closed

Liminatus Pharma, Inc. Class A Common Stock

LIMNNASDAQ·USD·Closed

$4.23

−3.86%

$4.23

−$0.17 (3.86%)

52W Range

0thpctl

Volume

0.07×avg

Mkt Cap

5.68MUSD

P/E

-0.2TTM

Div Yield

–ann